Verastem Inc. (VSTM)
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.6 per share a year ago.
Verastem (VSTM) Upgraded to Buy: Here's Why
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Verastem, Inc. (NASDAQ:VSTM ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel Calkins - Chief Financial Officer Daniel W. Paterson - President, CEO & Director Julissa Viana - Vice President of Corporate Communications & Investor Relations Matthew E.
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.31 per share a year ago.
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verastem: The Market Is Ignoring The Progress
FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point.
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competition remain notable challenges.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Verastem: Planning The PDUFA Run-Up
Verastem, Inc.'s NDA for avutometinib and defactinib in recurrent KRAS-mutant LGSOC has been accepted by the FDA, with a PDUFA date set for June 30, 2025. The combination therapy shows promising Phase II RAMP 201 results, with a 31% ORR and significant tumor size reduction, potentially positioning Verastem as a commercial-stage company by 2025. The LGSOC market is projected to reach $363.7M by 2034, with Verastem's therapy poised to capture a significant share due to the lack of approved treatments.
Verastem: BLA Acceptance Puts Key Goals In Sight
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves, with only 4-5 quarters of operating funds, posing a risk if there are approval delays. The market size for their therapy is uncertain, with potential revenues ranging from $85.7 million to $686 million annually.
